Archive to PDF: This thread can be removed from Twitter at anytime.
Archive this thread to PDF, save and print. It is a premium feature and costs $5 per month.
First up a study of pembrolizumab in patients with HIV and cancer. This is a critical question - patients were excluded from nearly every IO trial, due to concerns about lack of efficacy and increased toxicity. #ASCO19 h
Wide variety of CD4 counts included on this study, and they were rather heavily pretreated. They did not see a substantial change in CD4 counts with pembrolizumab. #ASCO19 h
Toxicity does not seem much worse than what would be expected for other patients with cancer treated with pembrolizumab. This is the key first point - pembro in patients with HIV seems to be safe. #ASCO19 h
And then the other main question - can pembro work in this patient population? Yes it can. They saw multiple responses, including a CR in NSCLC. Clearly patients with HIV can benefit from IO. Hard to compare ORR to other series given multiple included tumors #ASCO19 h
There was one very atypical case of a Grade 5 lymphoproliferative disorder. Unclear if this is from the pembro or underlying disease. #ASCO19 h
I think this is a very important study - patients with HIV deserve to be included in future IO trials congrats to the authors including @phase1oncomd and full manuscript is available now in @JAMAOnc#ASCO19 h
There are multiple ways to embed @Jbauml's unrolled
1. Direct link
2. Use iframe
Sharing is caring 😍
Like this thread of @Jbauml?
it with your friends & followers.
Love Thread Readers? Upgrade to premium to unlock all features
A whole new way to explore your interests. Convert your Thread to PDF,
save and print. Subscribe to interesting authors and be notified when new unroll is
available. Auto publish your threads on Medium and WordPress websites.